Literature DB >> 20965798

LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies.

Cyril V Abobo1, Lei Wu, Jyothy John, Mathew K Joseph, Theodore R Bates, Dong Liang.   

Abstract

Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is active against NNRT-resistant HIV-1. A simple, sensitive, and specific LC-MS/MS method was developed and validated for the analysis of etravirine in rat plasma using itraconazole as the internal standard. The analytes were extracted with ethyl acetate and chromatographed on a reverse-phase XTerra MS C₁₈ column. Elution was achieved with a mobile phase gradient varying the proportion of a 2 mM ammonium acetate aqueous solution containing 0.1% formic acid (solvent A) and a 0.1% formic acid in methanol solution (solvent B) at a flow rate of 300 μL/min. The analytes were monitored by tandem-mass spectrometry with positive electrospray ionization. The precursor/product transitions (m/z) in the positive ion mode were 435.9→163.6 and 706.7→392.6 for etravirine and the internal standard, respectively. Calibration curves were linear over the etravirine rat plasma concentration range of 1-100 ng/mL. The inter- and intra-day accuracy and precision were within ±10%. The assay has been successfully used for pharmacokinetic evaluation of etravirine using the rat as an animal model.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965798      PMCID: PMC3008212          DOI: 10.1016/j.jchromb.2010.09.016

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  15 in total

1.  Drug interactions with new and investigational antiretrovirals.

Authors:  Herta M Crauwels; Thomas N Kakuda
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 2.  Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.

Authors:  Jessica Adams; Nimish Patel; Nancy Mankaryous; Mariam Tadros; Christopher D Miller
Journal:  Ann Pharmacother       Date:  2009-12-08       Impact factor: 3.154

3.  Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

Authors:  Laura Else; Victoria Watson; John Tjia; Andrew Hughes; Marco Siccardi; Saye Khoo; David Back
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-04-09       Impact factor: 3.205

Review 4.  Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

Authors:  Laura Dickinson; Saye Khoo; David Back
Journal:  Antiviral Res       Date:  2009-08-07       Impact factor: 5.970

Review 5.  Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.

Authors:  Leonard B Johnson; Louis D Saravolatz
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

6.  Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.

Authors:  Sylvie Quaranta; Christian Woloch; Alexandre Paccou; Madeleine Giocanti; Caroline Solas; Bruno Lacarelle
Journal:  Ther Drug Monit       Date:  2009-12       Impact factor: 3.681

7.  A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.

Authors:  Naser L Rezk; Nicole R White; Steven H Jennings; Angela D M Kashuba
Journal:  Talanta       Date:  2009-06-09       Impact factor: 6.057

8.  Direct injection liquid chromatography/positive ion electrospray ionization mass spectrometric quantification of methotrexate, folinic acid, folic acid and ondansetron in human serum.

Authors:  Panagiotis Koufopantelis; Sophia Georgakakou; Michael Kazanis; Costas Giaginis; Alexandra Margeli; Sophia Papargiri; Irene Panderi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-10-02       Impact factor: 3.205

Review 9.  Clinical pharmacokinetics and pharmacodynamics of etravirine.

Authors:  Monika Schöller-Gyüre; Thomas N Kakuda; Araz Raoof; Goedele De Smedt; Richard M W Hoetelmans
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Warfarin-antiretroviral interactions.

Authors:  Michelle D Liedtke; R Chris Rathbun
Journal:  Ann Pharmacother       Date:  2009-02-05       Impact factor: 3.154

View more
  4 in total

1.  Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.

Authors:  Anna K Blakney; Yonghou Jiang; Dale Whittington; Kim A Woodrow
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-05-02       Impact factor: 3.205

2.  Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats.

Authors:  J John; M John; L Wu; C Hsiao; C V Abobo; D Liang
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 3.  Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.

Authors:  Iris Usach; Virginia Melis; José-Esteban Peris
Journal:  J Int AIDS Soc       Date:  2013-09-04       Impact factor: 5.396

Review 4.  Tandem mass spectrometry of small-molecule antiviral drugs: 1. HIV-related antivirals.

Authors:  W M A Niessen
Journal:  Int J Mass Spectrom       Date:  2020-06-15       Impact factor: 1.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.